• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, September 24, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Imagining perfect molecules using AI – a benchmarking system for generative chemistry

Bioengineer by Bioengineer
November 30, 2020
in Science News
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Insilico Medicine together with collaborators announces the publication of Molecular Sets (MOSES), a benchmarking system for generative chemistry models

IMAGE

Credit: Insilico

November 30, 2020 – Insilico Medicine, a leading company in AI-powered drug discovery, today announced that the paper titled “Molecular Sets (MOSES): A Benchmarking Platform for Molecular Generation Models” was published in Frontiers in Pharmacology. In addition to the authors from Insilico Medicine and Neuromation, the author list includes Simon Johansson and Hongming Chen from AstraZeneca, Benjamin Sanchez Lengeling from Harvard University, and Alan Aspuru-Guzik from Vector Institute, Department of Computer Science, University of Toronto, and Canadian Institute for Advanced Research (CIFAR).

In 2018, Insilico Medicine presented Molecular Sets (MOSES) benchmarking platform that was employed by multiple research groups since then. MOSES contains a carefully curated dataset, a set of metrics, and a wide variety of baselines for comparing generative models for chemistry. Over the last two years, we extended the repository with new baselines, enhanced evaluation protocols, and implemented simple routines for using MOSES out of the box. Today, Insilico Medicine announces that the manuscript describing the platform has been accepted for publication in Frontiers in Pharmacology, “Artificial intelligence for Drug Discovery and Development” special issue. The paper will soon be available here: https://www.frontiersin.org/articles/10.3389/fphar.2020.565644. For more information on MOSES, please visit the GitHub repository https://github.com/molecularsets/moses.

“With the rapid development of new generative chemistry, it is crucial to compare machine learning models in a unified way; with MOSES, we can easily compare new models with existing approaches without reimplementing all the baselines. MOSES is a result of tight collaboration between multiple generative chemistry labs; together we polished the platform over the last two years and made it as simple and intuitive as possible. We are glad to help researchers obtain interpretable, reproducible results with our platform.”, said Daniil Polikovskiy, senior author of the paper.

To cite the paper: https://www.frontiersin.org/articles/10.3389/fphar.2020.565644

###

Media Contact

For further information, images, or interviews, please contact: [email protected]

About Insilico Medicine

Insilico Medicine develops software that leverages generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with specific properties. Insilico Medicine also develops software for the generation of synthetic biological data, target identification, and the prediction of clinical trials outcomes. The company integrates two business models; providing AI-powered drug discovery services and software through its Pharma.AI platform (http://www.insilico.com/platform/) and developing its own pipeline of preclinical programs. The preclinical program is the result of pursuing novel drug targets and novel molecules discovered through its platforms. Since its inception in 2014, Insilico Medicine has raised over $52 million and received multiple industry awards. Insilico Medicine has also published over 100 peer-reviewed papers and has applied for over 25 patents. Website insilico.com

Media Contact
Polly Firs
[email protected]

Tags: AgingBiochemistryBioinformaticsBiotechnologyChemistry/Physics/Materials SciencesComputer ScienceGerontologyPharmaceutical Sciences
Share12Tweet8Share2ShareShareShare2

Related Posts

Sex Differences in Preterm Immune Responses and Hormone Effects

Sex Differences in Preterm Immune Responses and Hormone Effects

September 24, 2025
Optimizing Pangasius and Tilapia Marketing in Bangladesh

Optimizing Pangasius and Tilapia Marketing in Bangladesh

September 24, 2025

UVB Radiation’s Impact on Catla Catla Spawn

September 24, 2025

Boosting Lithium Battery Life via Flexible Current Collectors

September 24, 2025
Please login to join discussion

POPULAR NEWS

  • Physicists Develop Visible Time Crystal for the First Time

    Physicists Develop Visible Time Crystal for the First Time

    70 shares
    Share 28 Tweet 18
  • Tailored Gene-Editing Technology Emerges as a Promising Treatment for Fatal Pediatric Diseases

    50 shares
    Share 20 Tweet 13
  • Scientists Achieve Ambient-Temperature Light-Induced Heterolytic Hydrogen Dissociation

    49 shares
    Share 20 Tweet 12
  • Rapid Spread of Drug-Resistant Fungus Candidozyma auris in European Hospitals Prompts Urgent Warning from ECDC

    48 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Sex Differences in Preterm Immune Responses and Hormone Effects

Optimizing Pangasius and Tilapia Marketing in Bangladesh

UVB Radiation’s Impact on Catla Catla Spawn

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.